Peninsula Pharmaceuticals, Inc.
6
0
0
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
100%
6 trials in Phase 3/4
0%
0 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Doripenem in the Treatment of Hospital-Acquired Pneumonia
Role: collaborator
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Role: collaborator
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Role: collaborator
Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis
Role: collaborator
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
Role: collaborator
Doripenem in the Treatment of Ventilator-Associated Pneumonia
Role: collaborator
All 6 trials loaded